Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antiarrhythmic drug Clear all

Conditions: Atrial Fibrillation
Interventions: propafenone; flecainide; sotalol; dofetilide, Radiofrequency catheter ablation; Drug · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: No AAD post Ablation.; Other
Lead sponsor: Prisma Health-Midlands; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Atrial Fibrillation
Interventions: Dronedarone; Drug
Lead sponsor: American Heart Association; Other
Eligibility: 21 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 103
States / cities: Fairhope, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 78 more

Conditions: Arrythmia, Cardiomyopathies
Interventions: Intra-Op Prophylactic VT ablation, Conventional Management; Procedure · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 19
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more

Conditions: Atrial Fibrillation
Interventions: Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation; Drug · Other · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atrial Fibrillation, Atrial Fibrillation Recurrent
Interventions: dronedarone 400 mg Oral Tablet, Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 4
States / cities: Colorado Springs, Colorado • Atlanta, Georgia • New Orleans, Louisiana + 1 more

Conditions: Atrial Fibrillation, Atrial Fibrillation New Onset
Interventions: Cryoablation, Antiarrhythmic drug; Device · Drug
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 24
States / cities: Birmingham, Alabama • Anchorage, Alaska • Newport Beach, California + 21 more

Conditions: Healthy
Interventions: sotrastaurin, placebo to sotrastaurin, Avelox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tachycardia, Ventricular, Catheter Ablation
Interventions: Antiarrhythmic drug; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Ventricular Tachycardia
Interventions: amiodarone, sotalol, Biosense Webster's NAVI-STAR Thermo-Cool; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Baltimore, Maryland • Durham, North Carolina • Columbus, Ohio + 2 more

Conditions: Heart Diseases, Arrhythmia, Atrial Fibrillation
Interventions: NAVISTAR® THERMOCOOL® Catheter, Antiarrhythmic drug; Device · Drug
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 13
States / cities: Greenbrae, California • Orlando, Florida • Maywood, Illinois + 9 more

Conditions: Glaucoma, OHT - Ocular Hypertension
Interventions: Timolol 0.5% ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 30 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Rochester, Minnesota • Omaha, Nebraska • Columbus, Ohio

Conditions: Arrhythmia, Cardiac
Interventions: Catheter Ablation, Anti-Arrhythmics; Procedure · Drug
Lead sponsor: Kansas City Heart Rhythm Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Atrial Fibrillation
Interventions: Sotalol, Dofetilide; Drug
Lead sponsor: Samir Saba; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation
Interventions: Anti Arrhythmics, Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation; Drug · Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: Tucson, Arizona • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Atrial Fibrillation
Interventions: Cardiac CryoCor Cryoablation System, Medical management; Device · Drug
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 24
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 21 more

Conditions: Ventricular Tachycardia
Interventions: MRI guided VT ablation, Increased dose of amiodarone; Procedure · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Sudden Cardiac Death, Ventricular Tachycardia, Ventricular Fibrillation, Cardiomyopathy
Interventions: Cardiac Sympathetic Denervation (CSD), Routine Care; Procedure · Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Portland, Oregon • Nashville, Tennessee

Conditions: Arrhythmias
Interventions: Procainamide; Drug
Lead sponsor: Evan Adelstein, MD; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atrial Fibrillation, Stroke
Interventions: Catheter Ablation, Market-approved AVNB, OAC and AAD; Device · Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri

Conditions: Other Intraoperative Cardiac Functional Disturbances During Cardiac Surgery
Interventions: Lidocaine, Amiodarone, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Paroxysmal Atrial Fibrillation
Interventions: Radiofrequency ablation, antiarrhythmic drugs, Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs, ThermoCool Radiofrequency Catheter; Device · Drug
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 3
States / cities: Birmingham, Alabama • Boston, Massachusetts • Columbus, Ohio

Conditions: Atrial Fibrillation
Interventions: Pulmonary Vein Isolation performed by Catheter Ablation, Conventional Antiarrhythmic Drug Therapy; Procedure · Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 19 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Austin, Texas

Conditions: Atrial Fibrillation
Interventions: Ablation; Procedure
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of the Effectiveness of Anti-Arrhythmic Medications After Atrial Fibrillation Ablation

Comparison of Recurrence of Atrial Fibrillation Post Cryoballon Ablation During the 90-day Blanking Period-with and Without Anti-arrhythmic Drug Therapy

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation

The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients

Liraglutide Effect in Atrial Fibrillation

Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence

STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation

CAEB071 Thorough QTc Study in Healthy Volunteers

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Pilot Study of Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Symptomatic Paroxysmal Atrial Fibrillation

Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance

Catheter Ablation of Arrhythmias to Improve CRT Response

Improvement in Endothelial Dysfunction After Initiation of Anti-arrhythmic Therapy in Atrial Fibrillation Patients

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)

Safety and Efficacy of CryoCor™ Cryoablation for PAF

Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia

Cardiac Sympathetic Denervation for Prevention of Ventricular Tachyarrhythmias

Acute Mechanical Response to Anti-arrhythmic Drug Therapy

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

Amiodarone for the Prevention of Reperfusion Ventricular Fibrillation

A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation

First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)

Strategies in Patients Undergoing Repeat AF Ablation